ABOS: the cash flow

MyFinsight

The latest financial statement is for the year ending 2025-12-31.

Cash Flow	2025-12-31
Net loss	-121,335
Depreciation	58
Stock-based compensation expense	9,852
Amortization of premiums and accretion of discounts on marketable securities, net	809
Change in fair value of embedded derivatives	-460
Amortization of right-of-use asset	126
Realized gain on marketable securities	59
Noncash interest expense	1,288
Other noncash expense	0
Prepaid expenses and other current assets	-1,362
Other long-term assets	-40
Accounts payable	-5,094
Accrued clinical trial expenses	-4,728
Accrued expenses and other liabilities	3,301
Finance lease liability	0
Net cash used in operating activities	-115,538
Purchases of marketable securities	38,056
Proceeds from maturities and sales of marketable securities	172,077
Purchases of property and equipment	88
Net cash provided by investing activities	133,933
Proceeds from issuance of common stock, net of issuance costs	0
Proceeds from exercise of stock options	39
Payment for financing lease	0
Payments for deferred offering costs	0
Repurchase of common shares to pay employee withholding taxes	73
Net cash (used in) provided by financing activities	-34
Net change in cash and cash equivalents and restricted cash	18,361
Cash and cash equivalents and restricted cash at the beginning of the period	35,859
Cash and cash equivalents and restricted cash at the end of the period	54,220

Unit: Thousand (K) dollars (except for numbers of shares and EPS).